Alhazzani, Waleed
Møller, Morten Hylander
Arabi, Yaseen M.
Loeb, Mark
Gong, Michelle Ng
Fan, Eddy
Oczkowski, Simon
Levy, Mitchell M.
Derde, Lennie
Dzierba, Amy
Du, Bin
Aboodi, Michael
Wunsch, Hannah
Cecconi, Maurizio
Koh, Younsuck
Chertow, Daniel S.
Maitland, Kathryn
Alshamsi, Fayez
Belley-Cote, Emilie
Greco, Massimiliano
Laundy, Matthew
Morgan, Jill S.
Kesecioglu, Jozef
McGeer, Allison
Mermel, Leonard
Mammen, Manoj J. http://orcid.org/0000-0003-0343-3234
Alexander, Paul E.
Arrington, Amy
Centofanti, John E.
Citerio, Giuseppe
Baw, Bandar
Memish, Ziad A.
Hammond, Naomi
Hayden, Frederick G.
Evans, Laura
Rhodes, Andrew
Article History
Received: 15 March 2020
Accepted: 20 March 2020
First Online: 28 March 2020
Compliance with ethical standards
:
: Dr. Yaseen Arabi is the principal investigator on a clinical trial for lopinavir/ritonavir and interferon in Middle East respiratory syndrome (MERS) and he was a nonpaid consultant on antiviral active for MERS-coronavirus (CoV) for Gilead Sciences and SAB Biotherapeutics. He is an investigator on REMAP-CAP trial and is a Board Members of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). Dr. Eddy Fan declared receiving consultancy fees from ALung Technologies and MC3 Cardiopulmonary. Dr. Maurizio Cecconi declared consultancy work with Edwards Lifesciences, Directed Systems, and Cheetah Medical. Dr. Lennie Derde is the NVIC (Dutch National ICU society) chair of Taskforce Infectious Diseases (standing committee), member of ESICM Coronavirus Taskforce (started with this outbreak), chair ESICM Clinical Training Committee, all are unpaid positions. Dr. Frederick Hyden is non-compensated consultant to Gilead Sciences (antivirals for RVIS including remdesivir), Regeneraon (monoclonals for RVIs including MERS), and SAB Biotherapeutics (polyclonal antibodies for RVIs including MERS). Other authors declared no conflict of interest.
Free to read: This content has been made available to all.